Assessing white matter changes in mild cognitive impairment and Alzheimer's disease
Quantification of White Matter Hyperintensities in Subjects With Amnestic Mild Cognitive Impairment or Alzheimer's Disease
This study is testing how changes in brain white matter can help us understand and diagnose mild cognitive impairment and Alzheimer's disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 142 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | IRCCS Policlinico S. Donato Academic / other |
| Locations | 1 site (San Donato Milanese, Milano) |
| Trial ID | NCT06179680 on ClinicalTrials.gov |
What this trial studies
This observational study aims to quantify and analyze white matter hyperintensities in the brains of individuals diagnosed with amnestic mild cognitive impairment (aMCI) or Alzheimer's disease. Using magnetic resonance imaging (MRI), the study will measure the extent and distribution of these hyperintensities, which are indicative of underlying cognitive disorders. The findings may help in understanding the neuropathological processes associated with these conditions and could serve as potential biomarkers for early diagnosis and prognosis.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with amnestic mild cognitive impairment or Alzheimer's disease who are undergoing MRI as part of routine diagnostic procedures.
Not a fit: Patients with cognitive impairments other than amnestic MCI or Alzheimer's disease, or those with significant neurological disorders, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance early diagnosis and understanding of cognitive disorders, potentially leading to better management strategies.
How similar studies have performed: Other studies have indicated that assessing white matter hyperintensities can provide valuable insights into cognitive disorders, suggesting that this approach has been successful in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants diagnosed with amnestic Mild Cognitive Impairment (aMCI) or Alzheimer's Disease (AD) based on clinical assessments. * Individuals undergoing brain magnetic resonance imaging (MRI) at the IRCCS Policlinico San Donato as part of routine diagnostic procedures. * Age-matched and gender-matched healthy control subjects for comparison. Exclusion Criteria: * Individuals with cognitive impairment other than amnestic MCI or AD. * History of significant neurological disorders (other than MCI or AD) that may impact the study outcomes. * Presence of contraindications for undergoing MRI procedures. * Any serious medical or psychiatric condition that, in the judgment of the researchers, may interfere with the study participation or compromise the validity of the results. * Known history of alcohol or substance abuse that may affect cognitive function. * Inability or unwillingness to provide informed consent.
Where this trial is running
San Donato Milanese, Milano
- IRCCS Policlinico San Donato — San Donato Milanese, Milano, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.